-
1
-
-
0030451868
-
Incidence of inflammatory bowel disease across Europe: Is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD)
-
Shivananda S, Lennard-Jones J, Logan R, Fear N, Price A, Carpenter L, van Blankenstein M. Incidence of inflammatory bowel disease across Europe: is there a difference between north and south? Results of the European Collaborative Study on Inflammatory Bowel Disease (EC-IBD). Gut 1996; 39: 690-697
-
(1996)
Gut
, vol.39
, pp. 690-697
-
-
Shivananda, S.1
Lennard-Jones, J.2
Logan, R.3
Fear, N.4
Price, A.5
Carpenter, L.6
van Blankenstein, M.7
-
2
-
-
34248136340
-
Inflammatory bowel disease: Clinical aspects and established and evolving therapies
-
Baumgart DC, Sandborn WJ. Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet 2007; 369: 1641-1657
-
(2007)
Lancet
, vol.369
, pp. 1641-1657
-
-
Baumgart, D.C.1
Sandborn, W.J.2
-
3
-
-
0033778364
-
Tumor necrosis factor: Biology and therapeutic inhibitors
-
Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic inhibitors. Gastroenterology 2000; 119: 1148-1157
-
(2000)
Gastroenterology
, vol.119
, pp. 1148-1157
-
-
Papadakis, K.A.1
Targan, S.R.2
-
4
-
-
0037018761
-
Maintenance infliximab for Crohn's disease: The ACCENT I randomised trial
-
Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz D, Wolf DC, Olson A, Bao W, Rutgeerts P. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-1549
-
(2002)
Lancet
, vol.359
, pp. 1541-1549
-
-
Hanauer, S.B.1
Feagan, B.G.2
Lichtenstein, G.R.3
Mayer, L.F.4
Schreiber, S.5
Colombel, J.F.6
Rachmilewitz, D.7
Wolf, D.C.8
Olson, A.9
Bao, W.10
Rutgeerts, P.11
-
5
-
-
10744221312
-
Infliximab maintenance therapy for fistulizing Crohn's disease
-
Sands BE, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350: 876-885
-
(2004)
N Engl J Med
, vol.350
, pp. 876-885
-
-
Sands, B.E.1
Anderson, F.H.2
Bernstein, C.N.3
Chey, W.Y.4
Feagan, B.G.5
Fedorak, R.N.6
Kamm, M.A.7
Korzenik, J.R.8
Lashner, B.A.9
Onken, J.E.10
Rachmilewitz, D.11
Rutgeerts, P.12
Wild, G.13
Wolf, D.C.14
Marsters, P.A.15
Travers, S.B.16
Blank, M.A.17
van Deventer, S.J.18
-
6
-
-
0031759492
-
Advances in the management of Crohn's disease: Economic and clinical potential of infliximab
-
Hanauer SB, Cohen RD, Becker RV, Larson LR, Vreeland MG. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther 1998; 20: 1009-1028
-
(1998)
Clin Ther
, vol.20
, pp. 1009-1028
-
-
Hanauer, S.B.1
Cohen, R.D.2
Becker, R.V.3
Larson, L.R.4
Vreeland, M.G.5
-
7
-
-
3042579454
-
Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease
-
Hanauer SB, Wagner CL, Bala M, Mayer L, Travers S, Diamond RH, Olson A, Bao W, Rutgeerts P. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-553
-
(2004)
Clin Gastroenterol Hepatol
, vol.2
, pp. 542-553
-
-
Hanauer, S.B.1
Wagner, C.L.2
Bala, M.3
Mayer, L.4
Travers, S.5
Diamond, R.H.6
Olson, A.7
Bao, W.8
Rutgeerts, P.9
-
8
-
-
62049083383
-
Loss of response and requirement of infliximab dose intensification in Crohn's disease: A review
-
Gisbert JP, Panés J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-767
-
(2009)
Am J Gastroenterol
, vol.104
, pp. 760-767
-
-
Gisbert, J.P.1
Panés, J.2
-
9
-
-
33846242958
-
Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: The CHARM trial
-
Colombel JF, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65
-
(2007)
Gastroenterology
, vol.132
, pp. 52-65
-
-
Colombel, J.F.1
Sandborn, W.J.2
Rutgeerts, P.3
Enns, R.4
Hanauer, S.B.5
Panaccione, R.6
Schreiber, S.7
Byczkowski, D.8
Li, J.9
Kent, J.D.10
Pollack, P.F.11
-
10
-
-
32044451548
-
Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: The CLASSIC-I trial
-
quiz 591
-
Hanauer SB, Sandborn WJ, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh D, Panaccione R, Wolf D, Pollack P. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-333; quiz 591
-
(2006)
Gastroenterology
, vol.130
, pp. 323-333
-
-
Hanauer, S.B.1
Sandborn, W.J.2
Rutgeerts, P.3
Fedorak, R.N.4
Lukas, M.5
McIntosh, D.6
Panaccione, R.7
Wolf, D.8
Pollack, P.9
-
11
-
-
34249281002
-
Adalimumab for maintenance treatment of Crohn's disease: Results of the CLASSIC II trial
-
Sandborn WJ, Hanauer SB, Rutgeerts P, Fedorak RN, Lukas M, MacIntosh DG, Panaccione R, Wolf D, Kent JD, Bittle B, Li J, Pollack PF. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-1239
-
(2007)
Gut
, vol.56
, pp. 1232-1239
-
-
Sandborn, W.J.1
Hanauer, S.B.2
Rutgeerts, P.3
Fedorak, R.N.4
Lukas, M.5
McIntosh, D.G.6
Panaccione, R.7
Wolf, D.8
Kent, J.D.9
Bittle, B.10
Li, J.11
Pollack, P.F.12
-
12
-
-
33846615859
-
Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: A prospective, open-label, multicentre trial
-
Hinojosa J, Gomollón F, García S, Bastida G, Cabriada JL, Saro C, Ceballos D, Peñate M, Gassull MA. Efficacy and safety of short-term adalimumab treatment in patients with active Crohn's disease who lost response or showed intolerance to infliximab: a prospective, open-label, multicentre trial. Aliment Pharmacol Ther 2007; 25: 409-418
-
(2007)
Aliment Pharmacol Ther
, vol.25
, pp. 409-418
-
-
Hinojosa, J.1
Gomollón, F.2
García, S.3
Bastida, G.4
Cabriada, J.L.5
Saro, C.6
Ceballos, D.7
Peñate, M.8
Gassull, M.A.9
-
13
-
-
38149077059
-
The use of adalimumab in the management of refractory Crohn's disease
-
Ho GT, Smith L, Aitken S, Lee HM, Ting T, Fennell J, Lees CW, Palmer KR, Penman ID, Shand AG, Arnott ID, Satsangi J. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-315
-
(2008)
Aliment Pharmacol Ther
, vol.27
, pp. 308-315
-
-
Ho, G.T.1
Smith, L.2
Aitken, S.3
Lee, H.M.4
Ting, T.5
Fennell, J.6
Lees, C.W.7
Palmer, K.R.8
Penman, I.D.9
Shand, A.G.10
Arnott, I.D.11
Satsangi, J.12
-
14
-
-
58149302486
-
Adalimumab for Crohn's disease with intolerance or lost response to infliximab: A 3-year single-centre experience
-
Oussalah A, Babouri A, Chevaux JB, Stancu L, Trouilloud I, Bensenane M, Boucekkine T, Bigard MA, Peyrin-Biroulet L. Adalimumab for Crohn's disease with intolerance or lost response to infliximab: a 3-year single-centre experience. Aliment Pharmacol Ther 2009; 29: 416-423
-
(2009)
Aliment Pharmacol Ther
, vol.29
, pp. 416-423
-
-
Oussalah, A.1
Babouri, A.2
Chevaux, J.B.3
Stancu, L.4
Trouilloud, I.5
Bensenane, M.6
Boucekkine, T.7
Bigard, M.A.8
Peyrin-Biroulet, L.9
-
15
-
-
34249857135
-
Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: An open-label study
-
Peyrin-Biroulet L, Laclotte C, Roblin X, Bigard MA. Adalimumab induction therapy for ulcerative colitis with intolerance or lost response to infliximab: an open-label study. World J Gastroenterol 2007; 13: 2328-2332
-
(2007)
World J Gastroenterol
, vol.13
, pp. 2328-2332
-
-
Peyrin-Biroulet, L.1
Laclotte, C.2
Roblin, X.3
Bigard, M.A.4
-
16
-
-
34347402306
-
Adalimumab induction therapy for Crohn disease previously treated with infliximab: A randomized trial
-
Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Colombel JF, Panaccione R, D'Haens G, Li J, Rosenfeld MR, Kent JD, Pollack PF. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-838
-
(2007)
Ann Intern Med
, vol.146
, pp. 829-838
-
-
Sandborn, W.J.1
Rutgeerts, P.2
Enns, R.3
Hanauer, S.B.4
Colombel, J.F.5
Panaccione, R.6
D'Haens, G.7
Li, J.8
Rosenfeld, M.R.9
Kent, J.D.10
Pollack, P.F.11
-
17
-
-
7044226437
-
An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease
-
Sandborn WJ, Hanauer S, Loftus EV, Tremaine WJ, Kane S, Cohen R, Hanson K, Johnson T, Schmitt D, Jeche R. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99: 1984-1989
-
(2004)
Am J Gastroenterol
, vol.99
, pp. 1984-1989
-
-
Sandborn, W.J.1
Hanauer, S.2
Loftus, E.V.3
Tremaine, W.J.4
Kane, S.5
Cohen, R.6
Hanson, K.7
Johnson, T.8
Schmitt, D.9
Jeche, R.10
-
18
-
-
3543075236
-
A pilot study of adalimumab in infliximab-allergic patients
-
Youdim A, Vasiliauskas EA, Targan SR, Papadakis KA, Ippoliti A, Dubinsky MC, Lechago J, Paavola J, Loane J, Lee SK, Gaiennie J, Smith K, Do J, Abreu MT. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10: 333-338
-
(2004)
Inflamm Bowel Dis
, vol.10
, pp. 333-338
-
-
Youdim, A.1
Vasiliauskas, E.A.2
Targan, S.R.3
Papadakis, K.A.4
Ippoliti, A.5
Dubinsky, M.C.6
Lechago, J.7
Paavola, J.8
Loane, J.9
Lee, S.K.10
Gaiennie, J.11
Smith, K.12
Do, J.13
Abreu, M.T.14
-
19
-
-
0019319257
-
A simple index of Crohn's-disease activity
-
Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet 1980; 1: 514
-
(1980)
Lancet
, vol.1
, pp. 514
-
-
Harvey, R.F.1
Bradshaw, J.M.2
-
20
-
-
70350130547
-
Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
-
Karmiris K, Paintaud G, Noman M, Magdelaine-Beuzelin C, Ferrante M, Degenne D, Claes K, Coopman T, Van Schuerbeek N, Van Assche G, Vermeire S, Rutgeerts P. Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology 2009; 137: 1628-1640
-
(2009)
Gastroenterology
, vol.137
, pp. 1628-1640
-
-
Karmiris, K.1
Paintaud, G.2
Noman, M.3
Magdelaine-Beuzelin, C.4
Ferrante, M.5
Degenne, D.6
Claes, K.7
Coopman, T.8
van Schuerbeek, N.9
Van Assche, G.10
Vermeire, S.11
Rutgeerts, P.12
-
21
-
-
0037434552
-
Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
-
Baert F, Noman M, Vermeire S, Van Assche G, D' Haens G, Carbonez A, Rutgeerts P. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-608
-
(2003)
N Engl J Med
, vol.348
, pp. 601-608
-
-
Baert, F.1
Noman, M.2
Vermeire, S.3
van Assche, G.4
D' Haens, G.5
Carbonez, A.6
Rutgeerts, P.7
-
22
-
-
0037379792
-
Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: A randomized controlled trial
-
Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124: 917-924
-
(2003)
Gastroenterology
, vol.124
, pp. 917-924
-
-
Farrell, R.J.1
Alsahli, M.2
Jeen, Y.T.3
Falchuk, K.R.4
Peppercorn, M.A.5
Michetti, P.6
-
23
-
-
0036269445
-
The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: Results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial
-
St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, Keystone EC. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002; 46: 1451-1459
-
(2002)
Arthritis Rheum
, vol.46
, pp. 1451-1459
-
-
St Clair, E.W.1
Wagner, C.L.2
Fasanmade, A.A.3
Wang, B.4
Schaible, T.5
Kavanaugh, A.6
Keystone, E.C.7
-
24
-
-
33749432435
-
Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease
-
Maser EA, Villela R, Silverberg MS, Greenberg GR. Association of trough serum infliximab to clinical outcome after scheduled maintenance treatment for Crohn's disease. Clin Gastroenterol Hepatol 2006; 4: 1248-1254
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 1248-1254
-
-
Maser, E.A.1
Villela, R.2
Silverberg, M.S.3
Greenberg, G.R.4
-
25
-
-
41849135759
-
Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease
-
Ainsworth MA, Bendtzen K, Brynskov J. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-948
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 944-948
-
-
Ainsworth, M.A.1
Bendtzen, K.2
Brynskov, J.3
-
26
-
-
34347267600
-
Clinical response to adalimumab: Relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis
-
Bartelds GM, Wijbrandts CA, Nurmohamed MT, Stapel S, Lems WF, Aarden L, Dijkmans BA, Tak PP, Wolbink GJ. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007; 66: 921-926
-
(2007)
Ann Rheum Dis
, vol.66
, pp. 921-926
-
-
Bartelds, G.M.1
Wijbrandts, C.A.2
Nurmohamed, M.T.3
Stapel, S.4
Lems, W.F.5
Aarden, L.6
Dijkmans, B.A.7
Tak, P.P.8
Wolbink, G.J.9
-
27
-
-
53549083244
-
Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease
-
West RL, Zelinkova Z, Wolbink GJ, Kuipers EJ, Stokkers PC, van der Woude CJ. Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease. Aliment Pharmacol Ther 2008; 28: 1122-1126
-
(2008)
Aliment Pharmacol Ther
, vol.28
, pp. 1122-1126
-
-
West, R.L.1
Zelinkova, Z.2
Wolbink, G.J.3
Kuipers, E.J.4
Stokkers, P.C.5
van der Woude, C.J.6
|